# CAR-T cell therapy: Overview

Source page: https://www.materialinsights.org/technologies/car_t_cell_therapy/tech-overview/

#### What it does

The job the technology does for people, in a short paragraph

CAR-T therapy treats some blood cancers by turning a patient's own immune cells into cancer killers ^[1]. The first was approved in the United States in 2017 for children with acute lymphoblastic leukaemia ^[1, 3]. By 2025 seven CAR-T therapies were approved there, for leukaemias, lymphomas and multiple myeloma ^[1].

as of 2026-11-11

#### How it works

The working principle in plain words, step by step

T cells are white blood cells that kill infected or abnormal cells, but they often miss cancer. Doctors first collect the patient's blood and separate out the T cells ^[1]. In a manufacturer's laboratory the cells receive a new gene so that they make a chimeric antigen receptor, or CAR, on their surface ^[1, 3]. The changed cells are grown to hundreds of millions and infused back in one dose ^[1]. When a CAR locks onto its marker on a cancer cell, such as CD19 on leukaemia cells, the T cell is switched on, kills the cell and multiplies ^[4].

as of 2026-11-11

#### Key figures

The handful of numbers that size it up, each with its unit, year and source

| Figure | Value | Unit | Year | Source |
|---|---|---|---|---|
| CAR-T therapies approved by the US Food and Drug Administration | 7 | products | 2025 | ^[1] |
| Patients with complete remission after one dose in the trial behind Kymriah's approval | 83 | % | 2017 | ^[4] |
| Launch price of Kymriah, a one-time treatment | 475,000 | USD | 2017 | ^[5] |
| Time to make one patient's cells (low end of 3 to 5 weeks) | 3 | weeks | 2025 | ^[1] |
| Large cell lymphoma patients alive with no sign of cancer five years after treatment (more than) | 30 | % | 2025 | ^[1] |

as of 2026-11-11. The NCI figures carry the page's update date of 26 February 2025; the remission and price figures carry the 2017 publication year of those reports, as neither sentence gives a data year [1, 4, 5].

#### Where it is used

The main places and products the technology is found in

- B-cell acute lymphoblastic leukaemia in children and young adults
- Large B-cell and other lymphomas
- Multiple myeloma
- Chronic lymphocytic leukaemia
- Specialist cancer centres able to manage its side effects

as of 2026-11-11

#### Scale today

How much of it there is now: units in use, made each year and who uses it

**Installed**
: Seven therapies approved in the United States ^[1]

**Unit**
: approved products

**Year**
: 2025

**Note**
: No count of patients treated worldwide was found; each dose is made for one patient ^[1].

as of 2026-11-11

#### Sources

1. [CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers](https://www.cancer.gov/about-cancer/treatment/research/car-t-cells) National Cancer Institute (NIH), 2025
2. [FDA Approves Novartis' CAR-T Drug, First Gene Therapy Approval in US](https://www.pharmtech.com/view/fda-approves-novartis-car-t-drug-first-gene-therapy-approval-us-0) Pharmaceutical Technology, 2017
3. [FDA Approves Personalized Cellular Therapy for Advanced Leukemia (news release)](https://pennmedicine.org/news/news-releases/2017/august/fda-approves-personalized-cellular-therapy-for-advanced-leukemia) Penn Medicine, 2017
4. ['Historic Action': FDA Approves First CAR-T Therapy](https://www.raps.org/resource/historic-action-fda-approves-first-car-t-therap.html) Regulatory Affairs Professionals Society (RAPS), 2017

## Other sections

- [Summary](https://www.materialinsights.org/technologies/car_t_cell_therapy/index.md)
- [Science](https://www.materialinsights.org/technologies/car_t_cell_therapy/tech-science/index.md)
- [Evolution](https://www.materialinsights.org/technologies/car_t_cell_therapy/tech-evolution/index.md)
- [Materials](https://www.materialinsights.org/technologies/car_t_cell_therapy/tech-materials/index.md)
- [Energy footprint](https://www.materialinsights.org/technologies/car_t_cell_therapy/tech-energy-footprint/index.md)
- [Industries](https://www.materialinsights.org/technologies/car_t_cell_therapy/tech-industries/index.md)
